Pomalidomide-PEG3-OH

Cat. No.: HY-W924948: Data Sheet Handling Instructions Technical Support

Pomalidomide-PEG3-OH (compound 53b) is an E3 Ligase Ligand-Linker Conjugates consisting of a pomalidomide (HY-10984)-based cereblon ligand and a 3-unit PEG linker.

For research use only. We do not sell to patients.

Pomalidomide-PEG3-OH Chemical Structure

CAS No. : 2140807-36-7

Size	Stock	Quantity
5 mg	Get quote 3 - 4 weeks 2 - 3 weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
10 mg	Get quote 3 - 4 weeks 2 - 3 weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
25 mg	Get quote 3 - 4 weeks 2 - 3 weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
50 mg	Get quote 3 - 4 weeks 2 - 3 weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
100 mg	Get quote 3 - 4 weeks 2 - 3 weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
250 mg	Get quote 3 - 4 weeks 2 - 3 weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
500 mg	Get quote
1 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

View All E3 Ligase Ligand-Linker Conjugates Isoform Specific Products:

View All Isoforms

von Hippel-Lindau (VHL) MDM2 Cereblon cIAP1 Aryl Hydrocarbon Receptor TRIM21

Biological Activity
Purity & Documentation
References
Customer Review

Description

Pomalidomide-PEG3-OH (compound 53b) is an E3 Ligase Ligand-Linker Conjugates consisting of a pomalidomide (HY-10984)-based cereblon ligand and a 3-unit PEG linker^[1].

IC₅₀ & Target

Cereblon

Molecular Weight

405.40

Formula

C₁₉H₂₃N₃O₇

CAS No.

2140807-36-7

SMILES

O=C1NC(C(CC1)N2C(C3=C(C2=O)C(NCCOCCOCCO)=CC=C3)=O)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Data Sheet (266 KB) Handling Instructions (2659 KB)

References

[1]. Zhang X, Thummuri D, Liu X, Hu W, Zhang P, Khan S, Yuan Y, Zhou D, Zheng G. Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15;192:112186. [Content Brief]